Literature DB >> 6338571

Meningococcal disease: still with us.

H Peltola.   

Abstract

In spite of considerable success in the development of drugs and vaccines, the problem of disease due to Neisseria meningitidis is far from solved. As late as the 1970s, epidemics of meningococcal disease occurred in at least 30 countries in all parts of the world. Most of the epidemics were caused by group A organisms, but epidemics due to groups B and C also took place occasionally. The case/fatality rate was usually less than 10% among patients with true meningitis; among those with "pure" septicemia, it was as high as 70%. Children less than five years old are most prone to meningococcal disease, but mortality is often highest among young adults. Because close contacts of the index case are at considerable risk--at least several hundred times higher than in the rest of the population--they should be protected immediately with an appropriate antibiotic and, if possible, with a vaccine as well. At the present time, however, no vaccine is available for use against group B organisms, which in nonepidemic conditions are the most prevalent of all meningococci.

Entities:  

Mesh:

Year:  1983        PMID: 6338571     DOI: 10.1093/clinids/5.1.71

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  120 in total

1.  Long-term persistence of a discotheque-associated invasive Neisseria meningitidis group C strain as proven by pulsed-field gel electrophoresis and porA gene sequencing.

Authors:  K Riesbeck; P Orvelid-Mölling; H Fredlund; P Olcén
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

2.  Mutator clones of Neisseria meningitidis in epidemic serogroup A disease.

Authors:  Anthony R Richardson; Zhong Yu; Tanja Popovic; Igor Stojiljkovic
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

3.  Comparison of serogroup W-135 meningococci isolated in Sweden during a 23-year period and those associated with a recent hajj pilgrimage.

Authors:  P Mölling; A Bäckman; P Olcén; H Fredlund
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

4.  Direct and rapid identification and genogrouping of meningococci and porA amplification by LightCycler PCR.

Authors:  Paula Mölling; Susanne Jacobsson; Anders Bäckman; Per Olcén
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

Review 5.  Recognition, treatment and complications of meningococcal disease.

Authors:  F A Riordan; A P Thomson
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.022

6.  High case-fatality rates of meningococcal disease in Western Norway caused by serogroup C strains belonging to both sequence type (ST)-32 and ST-11 complexes, 1985-2002.

Authors:  I Smith; D A Caugant; E A Høiby; T Wentzel-Larsen; A Halstensen
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

7.  Analysis of damage to human ciliated nasopharyngeal epithelium by Neisseria meningitidis.

Authors:  D S Stephens; A M Whitney; M A Melly; L H Hoffman; M M Farley; C E Frasch
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

8.  Prognostic evaluation in meningococcal disease. A retrospective study of 115 cases.

Authors:  B Gårdlund
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

9.  Meningitis in a child due to Neisseria meningitidis group K.

Authors:  W D Grahlow; P Kuzemenská
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

10.  Meningococcal infections in Scotland 1972-82.

Authors:  R J Fallon; W M Brown; W Lore
Journal:  J Hyg (Lond)       Date:  1984-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.